AMC Entertainment (AMC) looks poised for a Santa rally and here’s...

0
Shares of AMC are currently trading at $7.63 but that could be the calm before the storm. As per Finviz.com, AMC sits...

Market’s could rally into Thank Giving Friday (QQQ)

0
In a light volume Thanksgiving week where not much news in the Macro environment is coming out in the U.S to change...

Popular News

MAKE IT MODERN

LATEST REVIEWS

Pasithea Therapeutics Corp (NASDAQ: KTTA) Expands IV Ketamine Therapy Availability In...

0
Pasithea Therapeutics Corp (NASDAQ: KTTA) has announced that its wholly-owned subsidiary, Pasithea Clinics, has expanded the availability of IV ketamine therapy to Florida and...

MAKE IT MODERN

PERFORMANCE TRAINING

Cortexyme Inc. (NASDAQ:CRTX) To Proceed With Phase 2/3 GAIN Atuzaginstat Study In Alzheimer’s Disease

0
Cortexyme Inc. (NASDAQ:CRTX) has announced that an independent Data Monitoring Committee  (DMC) has completed a pre-planned preliminary analysis and recommended the company...

Qualigen Therapeutics Inc (NASDAQ: OLGN) Presents Three Posters at the American Association of Cancer...

0
Qualigen Therapeutics (NASDAQ: OLGN) announced the presentation of three posters at the American Association of Cancer Research, New Orleans.

Amarin (NASDAQ:AMRN)Established That VASCEPA® can Reduce Ischemic Events In Individuals That Previously Had PCI

0
Amarin Corporation Plc. (NASDAQ:AMRN) has announced the presentation of REDUCE-IT® PCI at Transcatheter Cardiovascular Therapeutics Connect during the 32nd Cardiovascular Research Foundation annual scientific...

ERYTECH Pharma (NASDAQ: ERYP) Reports TRYbeCA-1 Clinical Trials Results Evaluating Eryaspase in Pancreatic Cancer...

0
ERYTECH Pharma (NASDAQ: ERYP) has reported topline results from the third phase TRYbeCA-1 Clinical study evaluating eryaspase as a second-line metastatic pancreatic cancer treatment...

Is a Bottom in Sight for CytoDyn Inc (OTCMKTS:CYDY)?

0
CytoDyn Inc (OTCMKTS:CYDY) just announced that a research paper entitled "Leronlimab (PRO 140) activity against 4-class drug resistant HIV-1 from Heavily Treatment...

MAKE IT MODERN

POPULAR

[/tdc_zone]